CN110426464A - The HPLC detection method of isomers in a kind of meglumine - Google Patents
The HPLC detection method of isomers in a kind of meglumine Download PDFInfo
- Publication number
- CN110426464A CN110426464A CN201910610024.1A CN201910610024A CN110426464A CN 110426464 A CN110426464 A CN 110426464A CN 201910610024 A CN201910610024 A CN 201910610024A CN 110426464 A CN110426464 A CN 110426464A
- Authority
- CN
- China
- Prior art keywords
- meglumine
- detection method
- isomers
- hplc detection
- chromatographic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title claims abstract description 66
- 229960003194 meglumine Drugs 0.000 title claims abstract description 56
- 238000001514 detection method Methods 0.000 title claims abstract description 26
- 238000004128 high performance liquid chromatography Methods 0.000 title claims abstract description 22
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 title claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000001212 derivatisation Methods 0.000 claims abstract description 27
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 15
- 239000010452 phosphate Substances 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- 239000011541 reaction mixture Substances 0.000 claims abstract description 11
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000010828 elution Methods 0.000 claims abstract description 7
- 238000010790 dilution Methods 0.000 claims description 16
- 239000012895 dilution Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 238000004458 analytical method Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000005259 measurement Methods 0.000 abstract description 2
- 238000005220 pharmaceutical analysis Methods 0.000 abstract description 2
- 238000004007 reversed phase HPLC Methods 0.000 abstract description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 28
- 239000012071 phase Substances 0.000 description 23
- 239000000523 sample Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WCIHGUTYEXLBLC-UHFFFAOYSA-N n,n-diethylethanamine;propan-2-one Chemical compound CC(C)=O.CCN(CC)CC WCIHGUTYEXLBLC-UHFFFAOYSA-N 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000006193 liquid solution Substances 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to Pharmaceutical Analysis technical field, in particular to the HPLC detection method of isomers in a kind of meglumine.This method comprises: under alkaline condition, derivative reaction being occurred for meglumine sample and di-tert-butyl dicarbonate, obtains meglumine derivatization reaction mixture；Meglumine derivatization reaction mixture is detected using reversed-phased high performace liquid chromatographic, obtains the purity of isomers in meglumine sample, chromatographic condition is as follows: C18 chromatographic column；Mobile phase A is the phosphate aqueous solution of volumn concentration 0.05%~0.15%；Mobile phase B is the mixed liquor of acetonitrile and methanol, gradient elution.This method provides a kind of derivatization method, carries out isomers analysis to the meglumine after derivatization using reversed-phase high performance liquid chromatography and ultraviolet combination, and establishes the HPLC analytical method of the isomers measurement to meglumine derivative.Issuable isomers in meglumine bulk pharmaceutical chemicals can be monitored, guarantee drug safety.
Description
Technical field
The present invention relates to Pharmaceutical Analysis technical field, in particular to the HPLC detection method of isomers in a kind of meglumine.
Background technique
Meglumine (N-Methyl-D-glucamine) is a kind of important bulk pharmaceutical chemicals, is usually used in medical domain.Its No. CAS
Are as follows: 6284-40-8, molecular formula C7H17NO5, molecular weight are as follows: and 195.21, chemical structure are as follows:
The chemical structural formula of its isomers are as follows:
Meglumine is often used as alkaline agent in pharmaceutical preparation, can form ion with cationic drug at low ph conditions
It is right, the dissolubility of insoluble drug is improved, has good solubilising to make some insoluble drugs such as Meloxicam, silibinin etc.
With.From the analysis of Production Technology of meglumine bulk pharmaceutical chemicals, it is possible to meglumine isomers can be generated, in order to guarantee drug safety,
Need to study the isomers in meglumine.Before this, the documents and materials of meglumine isomers analysis method are not found, therefore,
Need to provide a kind of HPLC detection method of meglumine isomers.
Summary of the invention
In view of this, the present invention provides a kind of HPLC detection methods of isomers in meglumine.This method can effectively divide
From meglumine and isomers, it can be achieved that the quality to bulk pharmaceutical chemicals controls.
In order to achieve the above-mentioned object of the invention, the present invention the following technical schemes are provided:
The present invention provides a kind of HPLC detection methods of isomers in meglumine, include the following steps:
Under alkaline condition, derivative reaction is occurred into for meglumine sample and di-tert-butyl dicarbonate, adds dilution, obtains
Meglumine derivatization reaction mixture；
Meglumine derivatization reaction mixture is detected using reversed-phased high performace liquid chromatographic, based on area normalization method
The content for calculating isomers in meglumine, obtains the purity of isomers in meglumine sample, chromatographic condition is as follows:
Chromatographic column: C18 chromatographic column；
Mobile phase A is the phosphate aqueous solution of volumn concentration 0.05%~0.15%；
Mobile phase B is the mixed liquor of acetonitrile and methanol, and the volume ratio of acetonitrile and methanol is (25~35): (65~75)；
Gradient elution program are as follows:
| Elution time | A phase (%) | B phase (%) |
| 0min | 90 | 10 |
| 15min | 70 | 30 |
| 16min | 70 | 30 |
| 30min | 20 | 80 |
。
Meglumine and its isomers are without UV absorption, in the present invention, are allowed to UV absorption using derivatization method and increase
By force, then by reversed-phase liquid chromatography it is tested and analyzed.
Preferably, mobile phase A is the phosphate aqueous solution of volumn concentration 0.1%.
Preferably, the volume ratio of acetonitrile and methanol is 30:70 in Mobile phase B.
Preferably, the packing material size of C18 chromatographic column is 3.0~5.0 μm, column length is 100~250mm, chromatographic column
Diameter is 2.0~4.6mm.
Preferably, C18 chromatographic column is Agilent Eclipse Plus-C18, and packing material size is 3.5 μm, and column length is
100mm, column diameter 4.6mm.
Preferably, Detection wavelength is 190~210nm.
Preferably, Detection wavelength 200nm.
Preferably, flow velocity is 0.8~1.2mL/min.
Preferably, flow velocity 1.0mL/min.
Preferably, column temperature is 28~32 DEG C.
Preferably, column temperature is 30 DEG C.
Preferably, sample volume is 8~12 μ L.
Preferably, sample volume is 10 μ L.
Preferably, the adjusting reagent of alkaline condition is triethylamine.
Preferably, dilution is the mixed liquor of 0.4vt%~0.6vt% phosphate aqueous solution and methanol.
Preferably, the volume ratio of 0.4vt%~0.6vt% phosphate aqueous solution and methanol is (1~3): (7~9).
Preferably, the concentration of meglumine derivatization reaction mixture is 5~10mmol/L.
Preferably, dilution is the mixed liquor of 0.5vt% phosphate aqueous solution and methanol.
Preferably, the volume ratio of 0.5vt% phosphate aqueous solution and methanol is 2:8.
Preferably, the concentration of meglumine derivatization reaction mixture is 6~8mmol/L.
The present invention provides a kind of HPLC detection methods of isomers in meglumine, this method comprises: under alkaline condition,
Derivative reaction is occurred into for meglumine sample and di-tert-butyl dicarbonate, adds dilution, obtains meglumine derivatization reaction mixture；
Meglumine derivatization reaction mixture is detected using reversed-phased high performace liquid chromatographic, calculates meglumine by area normalization method
The content of middle isomers obtains the purity of isomers in meglumine sample, and chromatographic condition is as follows: C18 chromatographic column；Mobile phase A is
The phosphate aqueous solution of volumn concentration 0.05%~0.15%；Mobile phase B is the mixed liquor of acetonitrile and methanol, acetonitrile and methanol
Volume ratio be (25~35): (65~75)；Gradient elution.It has the beneficial effect that:
This method provides a kind of derivatization method, using reversed-phase high performance liquid chromatography and ultraviolet combination to the Portugal after derivatization
Methylamine carries out isomers analysis, and establishes the HPLC analytical method of the isomers measurement to meglumine derivative.
Issuable isomers in meglumine bulk pharmaceutical chemicals can be monitored, guarantee drug safety.
Detailed description of the invention
Fig. 1: mixture chromatogram after meglumine and meglumine isomery derivatization；
Fig. 2: chromatogram after meglumine derivatization；
Fig. 3: chromatogram after meglumine isomery derivatization.
Specific embodiment
The invention discloses a kind of HPLC detection method of isomers in meglumine, those skilled in the art can use for reference this
Literary content, is suitably modified realization of process parameters.In particular, it should be pointed out that all similar substitutions and modifications are to art technology
It is it will be apparent that they are considered as being included in the present invention for personnel.Method and application of the invention has passed through preferably
Embodiment is described, related personnel obviously can not depart from the content of present invention, in spirit and scope to side as described herein
Method and application are modified or appropriate changes and combinations, carry out implementation and application the technology of the present invention.
Raw materials used medicine, reagent or instrument can be by the HPLC detection method of isomers in meglumine provided by the invention
Market is bought.
Below with reference to embodiment, the present invention is further explained:
Embodiment 1: the liquid-phase chromatographic analysis of meglumine and meglumine isomery derivatization product
High performance liquid chromatograph: Agilent 1260-VWD detector；
Mobile phase: A phase: 0.1% phosphate aqueous solution (V/V)；
B phase: acetonitrile: methanol=30:70 (V/V)；
Gradient:
1 gradient program of table
| Elution time | A phase (%) | B phase (%) |
| 0min | 90 | 10 |
| 15min | 70 | 30 |
| 16min | 70 | 30 |
| 30min | 20 | 80 |
Chromatographic column: Agilent Eclipse Plus-C18 4.6 × 100mm, 3.5 μm；
Detection wavelength: 200nm；
Flow velocity: 1.0mL/min；
Column temperature: 30 DEG C；
Sample volume: 10 μ L；
Dilution: 0.5% phosphoric acid water: methanol=2:8；
Sample solution is prepared: precision weighs meglumine about 130mg, is placed in 50mL vial, adds the water-soluble desampling of 0.8mL
Product are added 1.6mL triethylamine acetone soln (101mg/mL), add 0.8mL (BOC)2O acetone soln (500mg/mL) and
1.0mL acetone soln, reaction is stirred at room temperature to be terminated for 20 minutes.Add dilution to dissolve and be diluted to scale, mixes.
Isomery liquid solution is prepared: precision weighs meglumine isomers about 130mg, is placed in 50mL vial, adds 0.8mL water
Sample dissolution is added 1.6mL triethylamine acetone soln (101mg/mL), adds 0.8mL (BOC)2O acetone soln (500mg/
ML) and 1.0mL acetone soln, reaction is stirred at room temperature to be terminated for 20 minutes.Add dilution to dissolve and be diluted to scale, mixes.
Mixed solution is prepared: precision weighs sample about 130mg, is placed in 50mL vial, adds 0.8mL water sample dissolution,
It is added 1.6mL triethylamine acetone soln (101mg/mL), adds 0.8mL (BOC)2O acetone soln (500mg/mL) and 1.0mL
Acetone soln, reaction is stirred at room temperature to be terminated for 20 minutes.Precision pipettes 0.5mL isomery liquid solution and sets in above-mentioned volumetric flask, adds dilution
Liquid dissolves and is diluted to scale, mixes.
Testing result: result is referring to attached drawing 1-3, wherein RT=10.7min is the peak of meglumine derivatization product, RT=
11.3min is the peak of meglumine isomery derivatization product.
Comparative example 1: the liquid-phase chromatographic analysis of meglumine and meglumine isomery derivatization product
High performance liquid chromatograph: Agilent 1260-VWD detector；
Mobile phase: A phase: 0.1% phosphate aqueous solution (V/V)；
B phase: acetonitrile: methanol=30:70 (V/V)；
Gradient:
2 gradient program of table
| Elution time | A phase (%) | B phase (%) |
| 0min | 90 | 10 |
| 15min | 46 | 54 |
| 25min | 5 | 95 |
| 28min | 5 | 95 |
Chromatographic column: Agilent Eclipse Plus-C18 4.6 × 100mm, 3.5 μm；
Detection wavelength: 200nm；
Flow velocity: 1.0mL/min；
Column temperature: 30 DEG C；
Sample volume: 10 μ L；
Dilution: 0.5% phosphoric acid water: methanol=2:8；
Isomery liquid solution is prepared: precision weighs meglumine isomers about 130mg, is placed in 50mL vial, adds 0.8mL water
Sample dissolution is added 1.6mL triethylamine acetone soln (101mg/mL), adds 0.8mL (BOC)2O acetone soln (500mg/
ML) and 1.0mL acetone soln, reaction is stirred at room temperature to be terminated for 20 minutes.Add dilution to dissolve and be diluted to scale, mixes.
Mixed solution is prepared: precision weighs sample about 130mg, is placed in 50mL vial, adds 0.8mL water sample dissolution,
It is added 1.6mL triethylamine acetone soln (101mg/mL), adds 0.8mL (BOC)2O acetone soln (500mg/mL) and 1.0mL
Acetone soln, reaction is stirred at room temperature to be terminated for 20 minutes.Precision pipettes 0.5mL isomery liquid solution and sets in above-mentioned volumetric flask, adds dilution
Liquid dissolves and is diluted to scale, mixes.
Testing result is shown: meglumine derivatization product peak (RT=7.9min) and meglumine isomery derivatization product peak
(RT=8.0min), the separating degree at two peaks is 1.2.
Comparative example 2: the liquid-phase chromatographic analysis of meglumine and meglumine isomery derivatization product
High performance liquid chromatograph: Agilent 1260-VWD detector；
Mobile phase: A phase: 0.1% phosphate aqueous solution (V/V)；
B phase: acetonitrile: methanol=30:70 (V/V)；
Gradient:
3 gradient program of table
| Elution time | A phase (%) | B phase (%) |
| 0min | 90 | 10 |
| 15min | 46 | 54 |
| 25min | 5 | 95 |
| 28min | 5 | 95 |
Chromatographic column: Agilent ZORBAXSB-C18 4.6 × 250mm, 5 μm；
Detection wavelength: 200nm；
Flow velocity: 1.0mL/min；
Column temperature: 30 DEG C；
Sample volume: 10 μ L；
Dilution: 0.5% phosphoric acid water: methanol=2:8；
Isomery liquid solution is prepared: precision weighs meglumine isomers about 130mg, is placed in 50mL vial, adds 0.8mL water
Sample dissolution is added 1.6mL triethylamine acetone soln (101mg/mL), adds 0.8mL (BOC)2O acetone soln (500mg/
ML) and 1.0mL acetone soln, reaction is stirred at room temperature to be terminated for 20 minutes.Add dilution to dissolve and be diluted to scale, mixes.
Mixed solution is prepared: precision weighs sample about 130mg, is placed in 50mL vial, adds 0.8mL water sample dissolution,
It is added 1.6mL triethylamine acetone soln (101mg/mL), adds 0.8mL (BOC)2O acetone soln (500mg/mL) and 1.0mL
Acetone soln, reaction is stirred at room temperature to be terminated for 20 minutes.Precision pipettes 0.5mL isomery liquid solution and sets in above-mentioned volumetric flask, adds dilution
Liquid dissolves and is diluted to scale, mixes.
Testing result: meglumine derivatization product peak trails with meglumine isomery derivatization product peak, and separates not
It is good.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (10)
1. the HPLC detection method of isomers in a kind of meglumine, which comprises the steps of:
Under alkaline condition, derivative reaction is occurred into for meglumine sample and di-tert-butyl dicarbonate, adds dilution, obtains Portugal's first
Amine derivative reaction mixture；
Meglumine derivatization reaction mixture is detected using reversed-phased high performace liquid chromatographic, obtains isomery in meglumine sample
The purity of body, chromatographic condition are as follows:
Chromatographic column: C18 chromatographic column；
Mobile phase A is the phosphate aqueous solution of volumn concentration 0.05%~0.15%；
Mobile phase B is the mixed liquor of acetonitrile and methanol, and the volume ratio of the acetonitrile and the methanol is (25~35): (65~
75)；
Gradient elution program are as follows:
。
2. HPLC detection method according to claim 1, which is characterized in that the mobile phase A is volumn concentration
0.1% phosphate aqueous solution.
3. HPLC detection method according to claim 1, which is characterized in that in the Mobile phase B, the acetonitrile with it is described
The volume ratio of methanol is 30:70.
4. HPLC detection method according to claim 1, which is characterized in that the packing material size of the C18 chromatographic column is 3.0
~5.0 μm, column length is 100~250mm, and column diameter is 2.0~4.6mm.
5. HPLC detection method according to claim 1, which is characterized in that the detection of the reversed-phased high performace liquid chromatographic
Wavelength is 190~210nm.
6. HPLC detection method according to claim 1, which is characterized in that the flow velocity of the reversed-phased high performace liquid chromatographic
For 0.8~1.2mL/min.
7. HPLC detection method according to claim 1, which is characterized in that the column temperature of the reversed-phased high performace liquid chromatographic
It is 28~32 DEG C.
8. HPLC detection method according to claim 1, which is characterized in that the sample introduction of the reversed-phased high performace liquid chromatographic
Amount is 8~12 μ L.
9. HPLC detection method according to claim 1, which is characterized in that the adjusting reagent of the alkaline condition is three second
Amine.
10. HPLC detection method according to any one of claim 1 to 9, which is characterized in that the dilution is
The mixed liquor of 0.4vt%~0.6vt% phosphate aqueous solution and methanol, 0.4vt%~0.6vt% phosphate aqueous solution with it is described
The volume ratio of methanol is (1~3): (7~9)；
The concentration of meglumine derivatization reaction mixture is 5~10mmol/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910610024.1A CN110426464B (en) | 2019-07-08 | 2019-07-08 | HPLC detection method for isomers in meglumine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910610024.1A CN110426464B (en) | 2019-07-08 | 2019-07-08 | HPLC detection method for isomers in meglumine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110426464A true CN110426464A (en) | 2019-11-08 |
| CN110426464B CN110426464B (en) | 2022-03-04 |
Family
ID=68410361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910610024.1A Active CN110426464B (en) | 2019-07-08 | 2019-07-08 | HPLC detection method for isomers in meglumine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110426464B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115876899A (en) * | 2021-09-27 | 2023-03-31 | 长沙创新药物工业技术研究院有限公司 | Method for pretreating polyethylene glycol derivative sample and measuring content |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1771976A (en) * | 2004-11-09 | 2006-05-17 | 南京中医药大学 | Hepatoprotective preparation containing silibinin and Panax notoginseng glycosides and its preparation and quality control method |
| WO2008144728A1 (en) * | 2007-05-21 | 2008-11-27 | Bracco Imaging S.P.A. | Conjugates which bind a blood protein such as human serum albumin and methods of using the same in diagnostic and therapeutic applications |
| WO2013014659A1 (en) * | 2011-07-22 | 2013-01-31 | Venantius Limited | Indene derivatives for use in the treatment of inflammatory bowel disease |
| CN103592386A (en) * | 2013-11-09 | 2014-02-19 | 中国海洋大学 | Method for detecting monosaccharide and disaccharide and method for preparing derivatization reagents |
| US20140107194A1 (en) * | 2011-07-22 | 2014-04-17 | Venantius Limited | Compounds for use in the treatment of immune related inflammatory disease |
| CN106619636A (en) * | 2015-10-28 | 2017-05-10 | 重庆医药工业研究院有限责任公司 | Delafloxacin impurity compounds and preparation methods thereof |
-
2019
- 2019-07-08 CN CN201910610024.1A patent/CN110426464B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1771976A (en) * | 2004-11-09 | 2006-05-17 | 南京中医药大学 | Hepatoprotective preparation containing silibinin and Panax notoginseng glycosides and its preparation and quality control method |
| WO2008144728A1 (en) * | 2007-05-21 | 2008-11-27 | Bracco Imaging S.P.A. | Conjugates which bind a blood protein such as human serum albumin and methods of using the same in diagnostic and therapeutic applications |
| WO2013014659A1 (en) * | 2011-07-22 | 2013-01-31 | Venantius Limited | Indene derivatives for use in the treatment of inflammatory bowel disease |
| US20140107194A1 (en) * | 2011-07-22 | 2014-04-17 | Venantius Limited | Compounds for use in the treatment of immune related inflammatory disease |
| CN103592386A (en) * | 2013-11-09 | 2014-02-19 | 中国海洋大学 | Method for detecting monosaccharide and disaccharide and method for preparing derivatization reagents |
| CN106619636A (en) * | 2015-10-28 | 2017-05-10 | 重庆医药工业研究院有限责任公司 | Delafloxacin impurity compounds and preparation methods thereof |
Non-Patent Citations (5)
| Title |
|---|
| FOTOUH R. MANSOUR 等: "Multimodal liquid chromatography of small molecules", 《ANALYTICAL METHODS》 * |
| 岳云飞 等: "HPLC法测定葡甲胺中的有关物质", 《中国药品标准》 * |
| 张丽萍 等: "高效液相色谱法测定福沙匹坦二甲葡胺对映异构体", 《中国医院药学杂志》 * |
| 王霄等: "HPLC法测定犬血浆中的水飞蓟宾葡甲胺", 《中国天然药物》 * |
| 邓小娟 等: "柱前衍生化高效液相色谱法分离胺类对映异构体", 《分析测试》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115876899A (en) * | 2021-09-27 | 2023-03-31 | 长沙创新药物工业技术研究院有限公司 | Method for pretreating polyethylene glycol derivative sample and measuring content |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110426464B (en) | 2022-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mirza et al. | Determination of captopril in pharmaceutical tablets by anion-exchange HPLC using indirect photometric detection; a study in systematic method development | |
| CN104749269B (en) | A method of enantiomter impurity in Egelieting bulk pharmaceutical chemicals and preparation is measured using HPLC | |
| Amin et al. | Ion-pairing and reversed phase liquid chromatography for the determination of three different quinolones: enrofloxacin, lomefloxacin and ofloxacin | |
| Patel Madhavi et al. | Development and validation of improved RP-HPLC method for identification and estimation of ellagic and gallic acid in Triphala churna | |
| CN110687222B (en) | Compound ACC007 tablet content detection method and application | |
| Tsvetkova et al. | High performance liquid chromatographic assay of indomethacin and its related substances in tablet dosage forms | |
| Douša et al. | Liquid chromatographic separation of pregabalin and its possible impurities with fluorescence detection after postcolumn derivatization with o-phtaldialdehyde | |
| CN110426464A (en) | The HPLC detection method of isomers in a kind of meglumine | |
| CN104678031A (en) | Method for detecting atractyloside and/or hydroxyl atractyloside by virtue of high performance liquid chromatography | |
| CN104777263B (en) | Separation detection method of pregabalin chiral isomers | |
| Rajasingam et al. | Stress degradation studies and development of a validated RP-HPLC method for determination of tiagabine in presence of its degradation products | |
| Salem et al. | HPLC determination of indacaterol maleate in pharmaceutical preparations adopting ultraviolet and fluorescence detection | |
| Cateau et al. | Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography | |
| Główka et al. | Direct high-performance liquid chromatography method with refractometric detection designed for stability studies of treosulfan and its biologically active epoxy-transformers | |
| Martins et al. | Development of a dissolution test for lamotrigine in tablet form using an ultraviolet method | |
| Chorilli et al. | Development and validation of an analytical method by RP-HPLC for quantification of sibutramine hydrochloride in pharmaceutical capsules | |
| Alswayeh et al. | Rapid determination of acetaminophen levels in human plasma by high performance liquid chromatography | |
| Wassel et al. | Development and Validation of (HPLC) Method for Simultaneous Determination of Atomoxetine HCl & Fluoxetine HCl in their Pharmaceutical Dosage Forms | |
| CN112946135A (en) | Method for separating and measuring 3-amino-4-iminorifamycin S and related impurities | |
| CN103134861B (en) | Detection method of compound paracetamol and chlorphenamine maleate granules | |
| CN102375044B (en) | Method for analyzing related substance from hydrochloric acid bendamustine intermediate Z6 | |
| CN107976489B (en) | Method for determining residual pyridine in pregabalin | |
| Kumar et al. | A validated reversed phase HPLC-method for the determination of aceclofenac and tizanidine in tablets | |
| Bajerski et al. | Liquid chromatographic determination of cetirizine in oral formulations | |
| Binhashim et al. | A validated reversed phase HPLC assay for the determination of mefenamic acid in human plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Suzhou City, Jiangsu province 215000 Guan Hu Zhen Hu Qing Road No. 122 Applicant after: Suzhou Zhengji Pharmaceutical Co.,Ltd. Address before: Suzhou City, Jiangsu province 215000 Guan Hu Zhen Hu Qing Road No. 122 Applicant before: SUZHOU TIANMA PHARMACEUTICAL Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |